{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Infinity Pharmaceuticals, Inc.
Is Infinity Pharmaceuticals, Inc. overvalued or undervalued?
As of July 8, 2024, Infinity Pharmaceuticals, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with negative EV to EBIT and EV to EBITDA ratios, and significant underperformance compared to the S&P 500.
Is Infinity Pharmaceuticals, Inc. overvalued or undervalued?
As of October 15, 2023, Infinity Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 12.5, a P/B ratio of 1.2, and a D/E ratio of 0.5, indicating a strong balance sheet and trading at a discount compared to peers like Amgen and Vertex Pharmaceuticals.
Is Infinity Pharmaceuticals, Inc. technically bullish or bearish?
As of October 1, 2023, there is not enough technical data for Infinity Pharmaceuticals, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Infinity Pharmaceuticals, Inc.?
As of March 2022, the management team of Infinity Pharmaceuticals, Inc. includes Ms. Adelene Perkins as Chairman and CEO, along with Board members Mr. Norman Selby, Dr. Samuel Agresta, and independent directors Mr. David Beier, Dr. Anthony Evnin, and Dr. Richard Gaynor.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
